Deciphera Pharmaceuticals Inc DCPH

Healthcare Biotechnology

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

NDAQ:DCPH - Post by User

Deciphera Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by AviseAnalyticson Nov 10, 2021 7:01am

119 Views

Post# 34108553

AFTER A SETBACK, WHAT’S NEXT FOR DECIPHERA PHARMACEUTICALS?

$DCPH

Clinical-stage and commercial-stage companies offer an exciting investment opportunity with massive upside potential. However, even the slightest setback can prove detrimental to the existence of these companies. Failure to meet clinical endpoints, lack of funding or rejection from regulatory authorities are risks that these companies have to bear in pursuit of excellence.

We delve into Deciphera Pharmaceuticals (NASDAQ: DCPH) in our article today and see what's in store for the future!

Read on to know more!

https://www.aviseanalytics.com/after-a-setback-whats-next-for-deciphera-pharmaceuticals/

<< Previous

Bullboard Posts

Next >>

Theralase advances cancer research after private placement